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Declining brain and neurobiological function is arguably one of the most common
features of human aging. The study of conserved aging processes as well as the
characterization of various neurodegenerative diseases using different genetic models
such as yeast, fly, mouse, and human systems is uncovering links to non-coding
RNAs. These links implicate a variety of RNA-regulatory processes, including microRNA
function, paraspeckle formation, RNA–DNA hybrid regulation, nucleolar RNAs and toxic
RNA clearance, amongst others. Here we highlight these connections and reveal over-
arching themes or questions related to recently appreciated roles of non-coding RNA in
neural function and dysfunction across lifespan.
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Introduction
Neurodegenerative diseases are a group of debilitating neurological disorders typically associ-
ated with old age (Eacker et al., 2009). These conditions are characterized by the progressive
loss of neurons within one or more regions of the CNS (Eacker et al., 2009). Most neurode-
generative diseases are sporadic in origin, meaning that they arise in patients with no apparent
family history or known environmental cause (Robberecht and Philips, 2013). While the biology
of sporadic disease remains mysterious, several decades of research on various inherited forms
have led to remarkable advances in our understanding of disease genetics. Systematic eﬀorts
over the last few decades have led to the identiﬁcation of a number of causal mutations and
key genes (Pulst et al., 1996; Neumann et al., 2006; Kabashi et al., 2008). Building on these ﬁnd-
ings, many studies have attempted to delineate the precise pathological processes arising from
such genetic anomalies. A number of disease mechanisms have been proposed including toxic-
ity induced by misfolded or aberrantly translated proteins, and the mislocalization of important
cellular factors (Eacker et al., 2009). Despite encouraging progress, many aspects of these disorders
are poorly understood and sadly, many devastating conditions remain untreatable. Furthermore,
diseases for which symptom-relieving treatments are available are often diﬃcult to diagnose. As a
whole, neurodegenerative disease represents a major source of morbidity and mortality world-
wide and is justiﬁably garnering the attention of both the scientiﬁc community and society at
large.
Abbreviations: AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; AOA2, ataxia with oculomotor apraxia type 2;
ASO, antisense oligonucleotide; ATXN, Ataxin; BACE-1, beta-secretase 1; BCL, B-cell lymphoma; C9ORF72, Chromosome 9
open reading frame 72; CLP1, cleavage and polyadenylation factor 1 subunit 1; CNS, central nervous system;DN, dopaminer-
gic neuron; FTLD, frontotemporal lobar degeneration; FUS, fused in sarcoma; HD, Huntington’s disease; KLHL1, Kelch-like
1; lncRNA, long non-coding RNA; miRNA, microRNA; ncRNA, non-coding RNA; NEAT1, nuclear enriched abundant tran-
script 1; PCH, pontocerebellar hypoplasia; PD, Parkinson’s disease; RAN, repeat-associated non-ATG; RISC, RNA-induced
silencing complex; SCA, spinocerebellar ataxia; SETX, Senataxin; SIRT1, Sirtuin 1; TDP-43, TAR-DNA binding protein 43.
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Neurodegenerative diseases are associated with a diverse spec-
trum of clinical presentations, brain pathologies, and health
consequences (Eacker et al., 2009). They include relatively well-
known conditions like AD, FTLD, PD, and ALS. Additionally,
a host of less prevalent disorders including various SCAs and
AOA2 also belong to this class of diseases. Conditions, like AD
and FTLD are primarily cognitive disorders and represent the
two leading causes of dementia worldwide (Mattson, 2004). They
are caused by progressive loss of brain regions responsible for
reasoning, cognition, and memory. In contrast, ALS and PD
are chieﬂy disorders of motor function, caused by the preferen-
tial loss of motor neurons and dopamine-producing neurons in
the brain, respectively (Hardiman et al., 2011; Wirdefeldt et al.,
2011). Although some conditions can be contained by phar-
macotherapy and/or surgery, the majority of neurodegenera-
tive diseases remain untreatable. Furthermore, neurodegener-
ative diseases represent an increasing ﬁscal burden in health-
care systems attempting to cope with aging populations. Thus,
there is an urgent need to develop approaches that prevent,
stall, or cure neurodegenerative disease. Ultimately, this process
will hinge on understanding the precise molecular and cellular
mechanisms that lead to the premature dysfunction or death of
neurons.
Basic research on potential disease mechanisms has bene-
ﬁted greatly from studies using model organisms and/or novel
experimental systems. Insights from such studies are providing
mounting evidence that ncRNAs and ncRNA-regulatory pro-
cesses are important players in the pathogenesis of neurodegener-
ative disease (Eacker et al., 2009; Esteller, 2011; Abe and Bonini,
2013). ncRNAs represent a functionally and structurally diverse
class of RNA species that participate in a wide range of basic
cellular processes including protein translation, mRNA splic-
ing, chromatin organization, and the regulation of gene expres-
sion (Esteller, 2011). Several classes of ncRNAs (e.g., miRNAs,
rRNAs, tRNAs, and many lncRNAs) fulﬁll discrete functions
within cells. However, it is becoming clear that a large propor-
tion of the cellular transcript pool is comprised of ncRNAs that
lack obvious function (Djebali et al., 2012; Palazzo and Gregory,
2014). These entities are thought to derive primarily from
noisy transcription at intergenic sequences and are gener-
ally degraded rapidly within the nucleus (Djebali et al., 2012;
Palazzo and Gregory, 2014). However, recent studies suggest that
under certain conditions, these ncRNAs can trigger processes
that are toxic to cells (Figure 1). These processes include the
sequestration of crucial RNA-binding proteins as well as the
accumulation of genome-destabilizing R-loops, which are struc-
tures that can form when nascent RNA stably hybridizes with
DNA (Aguilera and Garcia-Muse, 2012; Haeusler et al., 2014;
Salvi et al., 2014). Accordingly, cells have evolved a number
of mechanisms to constrain both the amount and the abil-
ity of transcripts to engage in these detrimental processes
(Palazzo and Gregory, 2014; Salvi et al., 2014). In this review, we
focus exclusively on ncRNAs and make the broad distinction
between ncRNAs that are either functional or lack a discrete
role but nevertheless represent important determinants of over-
all cellular function. Speciﬁcally, we discuss the links between
neurodegenerative disease and two major classes of functional
ncRNAs, namely miRNAs and a group of lncRNAs. Additionally,
we explore emerging evidence that deleterious ncRNA-driven
processes such as R-loop formation and toxic RNA accumulation
represent neurotoxic mechanisms in brain aging and neurode-
generation.
Roles of miRNAs, lncRNAs, and other
ncRNAs in Neural Function and Aging
Introduction to miRNAs: Biogenesis and
Regulatory Mechanisms
microRNAs are an abundant class of short ncRNAs that regulate
a variety of cellular processes through the post-transcriptional
repression of gene expression (He and Hannon, 2004). Mature
miRNAs are generated following a series of well-orchestrated bio-
chemical events that begin in the nucleus and culminate in the
cytoplasm (Figure 2; Lee et al., 2002). These steps include the
nuclear processing of primary miRNA transcripts (pri-miRNAs)
into precursor miRNAs (pre-miRNAs) by the DGCR8/Drosha
complex, the cytoplasmic processing of pre-miRNAs into imper-
fectly paired miRNA duplexes by Dicer, and the preferential
incorporation of one strand (the “guide” miRNA strand) onto
the RISC (Bartel, 2004). Mature miRNAs complexed to RISC
(miRISC) are targeted to mRNAs containing sequences that
are complementary to the miRNA “seed” (nucleotides 2–7 of a
mature miRNA). Ultimately, the repression of mRNAs occurs via
their degradation, destabilization, translational silencing, or com-
binations thereof. Regardless of the speciﬁc mode of repression,
the ﬁnal outcome typically consists of decreased target protein
levels and a subsequent biological eﬀect reﬂecting the cellular
function of the targeted transcript.
microRNAs have been increasingly linked to processes asso-
ciated with brain aging, declining brain function, and neurode-
generative diseases (Eacker et al., 2009; Abe and Bonini, 2013).
Indeed, several studies have reported widespread changes in
miRNA expression, while others have identiﬁed speciﬁc miR-
NAs as strong correlates of brain aging and/or speciﬁc disease
states (Li et al., 2011a; Persengiev et al., 2011; Inukai et al., 2012;
Sheinerman et al., 2013). Future developments may allow these
correlations to be used as powerful diagnostic markers of neu-
rodegenerative diseases. In this section, we discuss the involve-
ment of miRNAs in regulating diverse aspects of neural func-
tion based on insights gained from various experimental and
genetic model systems. Furthermore, we highlight both direct
and indirect evidence for deregulation of miRNA pathways in
neurodegenerative disease.
miRNAs as Mediators of Brain Development
and Neuronal Differentiation
A crude but eﬀective approach to assess the overall role of miR-
NAs in the brain is to disable the miRNA biogenesis pathway
(Eacker et al., 2009). This can be accomplished by the condi-
tional deletion of Dicer, which results in a failure to generate
mature dicer-dependent miRNAs. It is important to note that
there have been reports of a relatively small number of dicer-
independent miRNAs, which would not be aﬀected by this
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FIGURE 1 | Summary of ncRNA-dependent processes implicated in
neurodegenerative disease. Diseases highlighted: AD, Alzheimer’s disease;
HD, Huntington’s disease; SCA8, spinocerebellar ataxia type 8; SCA2,
spinocerebellar ataxia type 2; ALS, amyotrophic lateral sclerosis; AOA2, ataxia
with oculomotor apraxia type 2; FXTAS, fragile X-associated tremor/ataxia
syndrome; and FTLD, frontotemporal dementia.
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FIGURE 2 | Proteins implicated in neurodegenerative diseases are
involved in multiple steps of the miRNA biogenesis pathway. TDP-43
and FUS (implicated in ALS and FTLD) interact with Drosha (directly and
indirectly respectively) to promote the processing of pri-miRNAs into
pre-miRNA. After export, TDP-43 also interacts with dicer to process
pre-miRNA into mature miRNA. When miRNA is loaded onto the RISC to
be targeted for silencing, it interacts with Ago1. In Drosophila, it was
shown that the protein Atx2 (the ortholog of ATXN2, a protein implicated in
ALS and SCA2) interacts with Ago1 to promote proper targeting of
miRNAs to their mRNA.
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strategy (Chelouﬁ et al., 2010; Ha and Kim, 2014). This strategy
applied tomodel organisms has nevertheless helped unearth roles
for miRNAs in developmental processes of the CNS including tis-
sue morphogenesis and neuronal diﬀerentiation. In zebraﬁsh, the
loss of maternal and zygotic Dicer manifests in abnormal organo-
genesis. A striking component of this phenotype includes severe
defects in neurulation and neural diﬀerentiation, which leads to
failed brain morphogenesis (Giraldez et al., 2005). Several stud-
ies in mice have investigated the developmental consequences of
disabling miRNA biogenesis in stem or neural precursor popu-
lations. One study used a Wnt1-cre promoter to conditionally
delete Dicer in neural crest cells and select regions of the brain
(Huang et al., 2010). This causes malformed development of the
cerebellum and midbrain, and impaired diﬀerentiation of neural
crest and dopaminergic cells. Similarly, the inactivation of Dicer
in olfactory and post-mitotic motor progenitors leads to a failure
to generate olfactory and post-mitotic motor neurons, respec-
tively (Choi et al., 2008; Chen andWichterle, 2012). The impor-
tance of miRNAs in neuronal diﬀerentiation is also supported
by studies employing cell culture models of diﬀerentiation. For
instance, the inactivation of miRNA biogenesis during the ﬁnal
stages of diﬀerentiation of DNs derived from murine embryonic
stem cells abolishes terminal diﬀerentiation in culture (Kim et al.,
2007b). Taken together, these studies identify miRNAs as crit-
ical players in fundamental brain development processes such
as neuronal diﬀerentiation. Thus, disruption of miRNA biogen-
esis can compromise neurodevelopmental and neural diﬀeren-
tiation processes that are known to occur at various stages of
life.
Roles for miRNAs in Neuronal Longevity and
Survival
Premature death of neurons is a major characteristic of neu-
rodegenerative diseases, and the root cause of many health
complications that arise during the course of illness. Mice have
been used extensively to address a wide variety of questions
relating to neuronal lifespan, including the need for a func-
tional miRNA pathway. To determine the role of miRNAs in the
maintenance of neuronal lifespan in vivo, several studies have
characterized the neurobiological phenotypes caused by the dele-
tion of Dicer in discrete populations of terminally diﬀerentiated
cells. In many cases, the absence of a functional miRNA path-
way leads to the loss of neurons via both cell autonomous and
non-cell autonomous mechanisms. The inactivation of Dicer in
post-mitotic murine midbrain neurons for instance, manifests
in a drastic reduction in number and axonal projection of DNs
residing in the midbrain as evidenced by decreased expression of
DN markers on immunohistochemical brain sections (Kim et al.,
2007b). Thismirrors the pathological changes observed in human
PD. Moreover, these degenerative changes are accompanied by
marked reductions in locomotion and mobility reminiscent of
bradykinesia (i.e., slowing of movement) seen during early stages
of PD (Kim et al., 2007b). Region-speciﬁc neurodegeneration
is observed in cerebellar Purkinje cells (PCs) devoid of Dicer
(Schaefer et al., 2007). Interestingly, 10-weeks-old wild-type and
Dicer-deﬁcient mice display no diﬀerences in morphology or
electrophysiological functions of PCs. Between 13 and 17 weeks,
Dicer-deﬁcient mice show profound PC apoptosis as revealed by
electron microscopy, immunohistochemistry, and TUNEL stain-
ing. Furthermore, cerebellar degeneration coincides with onset of
ataxia and a mild tremor that ultimately deteriorates to severely
impaired coordination and motor function. Similarly, condi-
tional deletion of Dicer in the spinal motor neurons results in
deteriorating motor function from week 7 onward and histolog-
ical changes in muscle that are pathognomonic for denervation-
induced muscular atrophy (Schaefer et al., 2007; Damiani et al.,
2008; Haramati et al., 2010). Indeed, spinal cord sections from
these mice display reduced numbers of lower motor neurons and
immunohistochemical evidence of reactive astrocytosis, which is
a marker of neurotoxicity (Schaefer et al., 2007; Damiani et al.,
2008; Haramati et al., 2010). Thus, the absence of a functional
miRNA pathway diminishes survival and recapitulates various
clinical and pathological features of human neurodegenerative
disease. This highlights the vital role of the miRNA pathway in
maintaining normal neuronal lifespan and points to the poten-
tial deregulation of this pathway as a driver or contributor to
neurodegeneration.
Neurons rely on many supporting cell types (astrocytes, oligo-
dendrocytes, Schwann cells, etc.) that co-exist in the nervous
system. Several studies have shown that defective miRNA bio-
genesis in these cells abrogates critical homeostatic functions
and lead to the death of neurons via non-cell autonomous
mechanisms. The loss of Dicer in astroglial cells results in
impaired neurotransmitter uptake and increased oxidative stress
(Tao et al., 2011). Disruption of these critical functions was
associated with ataxia at post-natal week 7, followed by pro-
longed seizures, severe locomotor dysfunction and eventually
premature organismal death. Immunohistochemistry in com-
bination with electron microscopy and TUNEL staining in
cerebellar sections revealed that these changes were precipi-
tated by apoptosis and axonal degeneration of mature cerebel-
lar granule cells and PCs, respectively. Similarly, the loss of
Dicer in Schwann cells and oligodendrocytes triggers inﬂam-
matory and oxidative cascades in the brain leading to neu-
ronal injury and degeneration (Shin et al., 2009; Bremer et al.,
2010). Thus, in the setting of neurodegenerative disease, loss
of key homeostatic functions downstream of miRNA biogen-
esis can induce non-cell autonomous neuronal degeneration
(Figure 1).
It is important to note that miRNAs are required for many
aspects of neuronal structure and function, not only their long-
term survival. In several studies, disabling miRNA biogene-
sis manifests in complex phenotypes in which degeneration
is preceded by structural and/or functional abnormalities. For
instance, Dicer inactivation in retinal cells results in the for-
mation of abnormal rosette structures composed of photore-
ceptors prior to degeneration (Damiani et al., 2008). Similarly,
the deletion of Dicer in cortical and hippocampal neurons
is associated with abnormalities in cellular morphology, tis-
sue architecture, and axonal pathﬁnding followed by profound
degeneration within these regions (Davis et al., 2008). Thus,
miRNA dysfunction may trigger overt neuronal degeneration as
well as more subtle deﬁcits in the setting of neurodegenerative
disease.
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Regulation of Neurodegenerative
Disease-Associated Pathways by miRNAs
While previously discussed studies tested the need for global
miRNA function in the brain, many other studies have focused
on the relevance of speciﬁc miRNAs or miRNA families in regu-
lating either neuroprotective or neurotoxic processes. One family
of miRNAs that has emerged as putatively protective is the miR-
29 family (Figure 1). Several studies employing mouse models
and human cell lines have examined the involvement of miR-
29 in neurodegenerative diseases. In agreement with a critical
role in the brain, miRNA proﬁling studies have reported that
miR-29a is expressed abundantly in neurons in the adult mouse
brain, while miR-29b expression increases in various compart-
ments of the maturingmouse CNS (Kole et al., 2011; Jovicic et al.,
2013). Consistent with a role in neuroprotection, diminished
levels of miR-29 family members have been reported in both
patients or mouse models of AD, HD, and various subtypes
of SCA (Lee et al., 2011; Wang et al., 2011b). The notion that
these patterns may represent disease-promoting mechanisms
rather than just correlational markers stems from the observa-
tion that perturbing miR-29 function is associated with com-
promised neuronal survival. For instance, knocking down miR-
29b in the mouse brain using LNA-based antagomirs induces
severe cerebellar and hippocampal degeneration, which man-
ifests in ataxia and eventually leads to death (Roshan et al.,
2014). This phenotype appears to be mediated in part by the
de-repression of VDAC1, an apoptotic eﬀector protein and
miR-29b target. Reduced miR-29b levels are also associated
with increased susceptibility to neuronal apoptosis in mouse
models of acute ischemic stroke (Khanna et al., 2013). In this
study, partial phenotypic rescue was achieved by the restora-
tion of miR-29b expression. Lastly, the miR-29 family may
also promote neuroprotection via the direct suppression of
disease-linked pathways (Figure 1). In the setting of AD, the
TABLE 1 | List of the various transcripts and proteins discussed in this review as well as their associated disease and proposed pathogenic mechanism.
Transcript/protein Organism studied Diseases
implicated
Proposed mechanism Reference
ban Fly SCA3, AD Suppresses neurodegeneration by inhibiting tau and
Ataxin-3
Bilen et al. (2006)
miR-8 Fly DRPLA Represses atrophin Ross et al. (1997); Karres et al. (2007)





Aging, SCA1 Represses ATXN1, other candidates Persengiev et al. (2011)
miR-34 Fly, worm, mouse,
human
AD Represses protective factors Bcl2 and SIRT1 Wang et al. (2009); Li et al. (2011b)
TDP-43 Mouse, human ALS, FTLD Interacts with Drosha to facilitate processing of miRNAs Kawahara and Mieda-Sato (2012)
miR-132 Human ALS Neural outgrowth factor regulated by TDP-43 and FUS Kawahara and Mieda-Sato (2012);
Morlando et al. (2012)
FUS/TLS Human ALS, FTLD Indirect Drosha interactions regulates various miRNAs Morlando et al. (2012)
ATX2 Fly ALS, SCA2, PSP Interactions with RISC components regulates long-term
habituation
McCann et al. (2011)
DGCR8 Human Prader–Willi
syndrome
Microprocessor, can process miRNAs and snoRNAs Macias et al. (2012)
n-Tr20 Mouse N/A. Neural cell
death observed
with mutation
tRNA isodecoder necessary for the production of
GTPBP2
Ishimura et al. (2014)
CLP1 Human PCH 10 Necessary for maturation of tRNAs Schaffer et al. (2014)
BACE1AS Human AD Stabilization of BACE1 which ultimately results in amyloid
beta accumulation
Faghihi et al. (2008)
ATXN8OS Human SCA8 May reduce the amount of KLHL1, may produce toxic
dipeptides or sequester RNA binding proteins
Chen et al. (2008b); Zu et al. (2011);
Tsoi et al. (2012)
UCHL1-AS Mouse AD, PD Regulates translation of neuroprotective protein UCHL1 Carrieri et al. (2012)
NEAT1 Mouse, human ALS, HD, aging Produces paraspeckle bodies which storage RNAs,
potentially for release during stress
Prasanth et al. (2005); Johnson (2012);
Abdelmohsen et al. (2013);
Nishimoto et al. (2013)
C9ORF72 Fly, human ALS Abortive transcripts sequester RNA binding proteins and
produce toxic dipeptides
Haeusler et al. (2014); Mizielinska et al.
(2014)
SETX Human, yeast AOA2, ALS RNA–DNA helicase prevents R-loop formation Skourti-Stathaki et al. (2011);
Yuce and West (2013)
Pbp1 Yeast ALS, SCA2, PSP Interacts with RNAs to prevent RNA–DNA hybrids,
maintains genomic stability, and cellular lifespan
Salvi et al. (2014)
Transcripts are indicated by italicized text, while proteins are underlined.
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expression of miR-29a/b-1 is inversely associated with BACE-1
levels (Hebert et al., 2008). BACE-1 is an enzyme that can cleave
amyloid precursor protein (APP) into amyloid beta (Aβ) pep-
tides, the chief component of Aβ plaques found in the brains of
AD patients (O’Brien andWong, 2011). In human cell linesmod-
eling Aβ plaque formation, miR-29a/b-1 can directly suppress
the expression of BACE-1 via direct seed-3′ UTR interactions
and reduce Aβ plaque formation in vitro (Hebert et al., 2008).
These results suggest that in disease states like AD, downregula-
tion of miR-29a/b-1 may promote disease susceptibility and/or
progression in patients by precipitating Aβ plaque formation.
Overall, functional studies focusing on miR-29 align well with its
inverse association with neurodegenerative disease and point to a
conserved role for this miRNA family in neuroprotection.
Examples of protective miRNAs that can directly target
disease-associated proteins also exist in Drosophila melanogaster.
For instance, the ban miRNA potently suppresses neurode-
generation induced by polyglutamine Ataxin-3 and tau,
pathogenic proteins that are causally linked to SCA3 and AD,
respectively (Bilen et al., 2006). Similarly, Drosophila miR-8
functions as a neuroprotective factor by targeting atrophin,
a family of proteins linked to the neurodegenerative disease
dentatorubral-pallidoluysian atrophy (DRPLA; Figure 1;
Ross et al., 1997; Karres et al., 2007). These results raise the
possibility that analogous pathways exist in humans, and
future studies that explore this further may furnish novel
opportunities for miRNA-based therapeutic targeting of disease
proteins.
While some miRNAs are clearly protective, others may pro-
mote brain aging and/or initiate neurotoxic processes that con-
tribute to speciﬁc neurodegenerative diseases (Table 1). For
instance, miR-144 is a strong positive correlate of aged brains
in humans, chimpanzees, and rhesus macaques (Persengiev et al.,
2011). miR-144 is also enriched in post-mortem tissue from SCA1
and AD patients. Importantly, the ATXN1 protein (encoded
by the gene mutated in SCA1) is a known target of miR-
144. Thus, age-associated miR-144 may contribute to declin-
ing brain function in both normal and disease states via
the downregulation of longevity/protective factors (Figure 1;
Persengiev et al., 2011). Similarly, studies in bothD. melanogaster
and Caenorhabditis elegans point to the miR-34 family as another
important determinant of brain aging. The miR-34 family is
a highly conserved set of brain-enriched miRNAs (Bak et al.,
2008). Intriguingly, correlative studies in mice and humans seem
to point to a potential role for miR-34 in AD. Brain tissue
derived from a mouse model of AD and in post-mortem tis-
sue from AD patients are enriched for miR-34a (Wang et al.,
2009). Interestingly, the pro-survival protein Bcl2 is a known
miR-34a target. Furthermore, the expression of another known
target of miR-34a, namely the anti-aging factor SIRT1, correlates
inversely with age-associated increases in brain and circulating
levels of that miRNA (Li et al., 2011b). SIRT1 knockdown acceler-
ates neurodegeneration due to mutant HTT in mouse models of
HD, while overexpression rescues phenotypes (Jiang et al., 2012).
Moreover, SIRT1 promotes neuronal survival and suppresses
neurodegeneration in a mouse model of AD and ALS (Kim et al.,
2007a). Similarly, several reports are consistent with the notion
that SIRT1 is neuroprotective (Araki et al., 2004; Chen et al.,
2008a; Shindler et al., 2010; Huang et al., 2011; Graﬀ et al., 2013).
However, overt neurodegenerative defects have not yet been
clearly documented in SIRT1-null mice, which nonetheless
exhibit neural migration defects (Di Sante et al., 2015). Thus,
SIRT1 may be simply neuroprotective or compensatory processes
mediated by other sirtuin proteins may be involved. Consistent
with the latter rationale, Sirt6 modulates neural chromatin struc-
ture and gene activity (Schwer et al., 2010). Taken together,
while the precise links between neurodegeneration and miR-
34a remain unclear, repression of protective factors such as Bcl2
and SIRT1 by the latter miRNA may point to two non-mutually
exclusive possibilities.
miRNA Dysfunction Downstream of
Disease-Associated Proteins
Several neurodegenerative diseases are associated with defects
in key RNA-binding proteins including TDP-43, ATXN2, and
FUS. TDP-43 and FUS have roles in the regulation of coding
RNAs which we do not discuss here and instead refer read-
ers to several excellent reviews about TDP-43 and FUS func-
tion (Lagier-Tourenne and Cleveland, 2009; Baloh, 2012). In this
section, we explore emerging evidence linking these disease-
associated proteins with putative miRNA-regulatory functions
and suggest how disruption of these roles may trigger pathologi-
cal cascades in neurodegenerative diseases.
Tar-DNAbinding protein-43 is a ubiquitously expressed RNA-
binding protein strongly linked to several neurodegenerative
diseases. Mutation of TARDBP (encodes TDP-43) is a relatively
rare cause of familial ALS (Kabashi et al., 2008). Moreover, TDP-
43 protein is frequently mislocalized to ubiquitinated inclusion
bodies in ALS/FTLD, pointing to a role in disease pathogene-
sis even in the absence of TARDBP mutations (Neumann et al.,
2006). In healthy cells, TDP-43 is primarily nuclear and it fulﬁlls
diverse roles in the regulation of mRNA transcription, alter-
native splicing, and ncRNA stability (Robberecht and Philips,
2013). However, it is becoming increasingly apparent that TDP-
43 may additionally act as a regulator of miRNA biogenesis
and function. Indeed, TDP-43 has been shown to physically
interact with Drosha and Dicer in the nucleus and cytoplasm
respectively, and these interactions are required for the normal
processing of several miRNAs (Kawahara and Mieda-Sato, 2012).
Furthermore, TDP-43 can either enhance or diminish the target-
ing of mRNAs by speciﬁc miRNAs (Fan et al., 2014; King et al.,
2014). These results identify TDP-43 a component of the miRNA
pathway and raise the possibility that mutations and/or mislo-
calization of TDP-43 may disrupt the biogenesis and/or func-
tion of miRNAs (Figure 2). Indeed, knocking down TDP-43
impairs neuronal diﬀerentiation of mouse neuroblastoma cells
in culture due in part to a failure to properly process pri-miR-
132, a miRNA with extensive links to neuronal diﬀerentiation
(Kawahara and Mieda-Sato, 2012). Additionally, altered expres-
sion proﬁles of multiple TDP-43-regulated miRNAs is observed
in serum and lymphoblast cell lines derived from ALS patients
(Freischmidt et al., 2013). Taken together, these studies suggest
that miRNA dysfunction downstream of disease-linked TDP-43
alterations could represent an important pathogenic mechanism
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in neurodegenerative disease and warrants further investigation
(Figure 1).
Fused in sarcoma is another RNA-binding protein impli-
cated in ALS/FTLD (Kwiatkowski et al., 2009; Vance et al., 2009;
Mackenzie et al., 2010). The neuropathology of FUS is remark-
ably similar to TDP-43 in terms of detection in aberrant
cytoplasmic aggregates within aﬀected CNS regions. Unlike
TDP-43, FUS shows no direct interaction with Drosha or
Dicer (Kawahara and Mieda-Sato, 2012). However, nuclear FUS
directly binds pri-mRNA, including the neural outgrowth factor
pri-miR-132 (Morlando et al., 2012). Depletion of FUS decreases
Drosha levels at miRNA genes, suggesting that FUS facili-
tates miRNA processing through indirect Drosha interactions
(Morlando et al., 2012). FUS also regulates miR-134 and miR-
143, both of which display diﬀerential neural expression with age
(Inukai et al., 2012). Therefore, similarly to TDP-43, FUS may be
required in the nucleus to maintain proper miRNA expression in
the aging brain (Figure 2).
The ATXN2 protein is yet another disease-associated RNA
binding protein with a putative role inmiRNA function. Aberrant
polyglutamine expansion within the human ATXN2 gene causes
spinocerebellar ataxia type 2 (SCA2) and is strongly linked to
ALS as well as the atypical parkinsonian disorder called pro-
gressive supranuclear palsy (PSP; Pulst et al., 1996; Elden et al.,
2010; Ross et al., 2011). Atx2, the D. melanogaster ortholog of
ATXN2, plays a critical role in long-term habituation of adult
olfactory projection neurons via an Ago1- and Me31B- depen-
dent mechanism (McCann et al., 2011). Both proteins are core
components of the miRNA pathway in ﬂies, thus identifying Atx2
as an important component of the D. melanogastermiRNA path-
way (Figure 2). Overall, these ﬁndings raise the possibility that
mutations and/or mislocalization of key RNA binding proteins
including TDP-43, FUS, and ATXN2 (Figure 1) may lead to the
disruption miRNAs that otherwise fulﬁll critical functions in the
brain.
All in all, the miRNA pathway in general and speciﬁc miRNAs
in particular are emerging as key players in the nervous system
as they are linked to neurogenesis, cell survival/longevity, and a
healthy/functional lifespan. However, as we will see in the next
section, miRNAs are not the only type of ncRNA with such roles.
Other Small ncRNAs in Neurodegenerative
Disease
In addition to miRNAs, a wide variety of small ncRNAs
exists. Data linking these latter transcripts with neurodegener-
ative disorders are relatively limited (Esteller, 2011). However,
there is some evidence that neurodegeneration-linked pro-
teins may be responsible for proper regulation of such small
ncRNAs. For example, the microprocessor DGCR8 regulates
hundreds of small nucleolar RNAs (snoRNAs) independently
of Drosha in human cells (Macias et al., 2012). It is impor-
tant to note that although DGCR8 is also involved in the
processing of miRNAs via Drosha interaction, miRNAs are
not the most abundant DGCR8 targets (Macias et al., 2012).
Furthermore, DGCR8 co-puriﬁes with TDP-43 making it a puta-
tive regulator of snoRNA biogenesis (Kawahara and Mieda-Sato,
2012; Macias et al., 2012). Interestingly, defects in snoRNAs are
associated with neurodevelopmental disorders such as Prader–
Willi syndrome (Sahoo et al., 2008). Furthermore, several snoR-
NAs are diﬀerentially expressed in aged rat brains, so micro-
processor action may also be important for the maintenance
of proper snoRNA regulation during aging (Wood et al., 2013).
Therefore, it is possible that the mislocalization of TDP-43
in ALS, FTLD or AD may impair DGCR8 function. This
would in turn inhibit the biogenesis of key neural snoRNAs.
Further work is clearly needed to clarify how TDP-43 or other
neurodegeneration-related proteins impact snoRNA biogenesis
and how this is important for the maintenance of neuronal and
brain function.
tRNAs represent another ubiquitous and vital group of small
ncRNAs. They recognize RNA codon sequences and allow for
the transfer of amino acids, thereby mediating the process
of protein synthesis. tRNAs that recognize the same codon,
termed isodecoders, are encoded by numerous nuclear genes
(Goodenbour and Pan, 2006). These isodecoders are not redun-
dant; mutation of a CNS-speciﬁc tRNA isodecoder in mice,
n-Tr20, is suﬃcient to cause the loss of a protein, GTPBP2,
and results in widespread neurodegeneration (Ishimura et al.,
2014). This highlights the importance of individual tRNAs in
maintaining neural health. Additionally, mutations in aminoacyl-
tRNA synthetases, which match tRNAs with their respec-
tive amino acids, leads to neurodegeneration (Lee et al., 2006).
Finally, ﬁdelity of the tRNA splicing pathway is important for
maintaining proper brain health. Individuals with a mutation
in the kinase CLP1 have very early onset neurodegeneration,
termed PCH10. This is likely at least in part due to the role
CLP1 plays in the maturation of tRNAs as patient neurons
are deﬁcient in mature tRNAs and accumulate unspliced pre-
tRNAs. Additionally, transfection of tRNA fragments into patient
cells exacerbates neurodegenerative phenotypes (Schaﬀer et al.,
2014). All in all, the proper genesis and function of dif-
ferent types of small ncRNAs is important for maintain-
ing neural cell populations and preventing neurodegenerative
disease.
Introduction to lncRNAs
Long non-coding RNAs are a heterogeneously deﬁned group of
RNAs, many of which are emerging as regulators of genome
expression/stability and modulators of neural function and dys-
function (Figure 1; Wu et al., 2013). LncRNAs can be gener-
ally deﬁned as non-coding transcripts that are greater than
200 nucleotides in length (Esteller, 2011). Many lncRNAs are
molecularly indistinguishable from mRNAs; they are also pro-
duced by Pol II and undergo 5′ capping and polyadenylation
(Ip and Nakagawa, 2012). Despite the fact that lncRNAs are not as
well-characterized as miRNAs or coding transcripts, they actually
make up the majority of the mammalian transcriptome (Esteller,
2011). There are a variety of mechanisms through which lncRNAs
can impact gene expression. For example, lncRNAs can inhibit or
promote transcription through the recruitment of histone modi-
fying complexes or through the binding of speciﬁc transcriptional
regulators (Geisler and Coller, 2013). lncRNAs are also capable
of altering translation through binding to mRNAs and forming
duplexes which can promote stability, alter splicing proﬁles or
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mask miRNA binding sites (Geisler and Coller, 2013). Here, we
highlight how lncRNAs can impact neurodegeneration.
Antisense lncRNAs Regulate Sense
Transcription of Neural Factors
In the context of neurodegenerative diseases, antisense tran-
scripts have emerged as regulators of neural proteins. Antisense
transcripts are often lncRNA transcripts that emerge from the
opposite strand of a coding RNA region. One such transcript
is BACE1AS, which is upregulated in AD (Faghihi et al., 2008).
BACE1AS stabilizes its sense transcript BACE1 through the for-
mation of an RNA duplex and this increases production of the
BACE1 protein (Faghihi et al., 2008). Excess BACE1 then leads
to sequential cleavage of the APP to form Aβ peptides, which
constitute the amyloid plaques that are characteristic of AD
pathobiology (Faghihi et al., 2008). Indeed, both a mouse and a
human cell line model of AD demonstrated delayed plaque for-
mation following BACE1AS knockdown (Modarresi et al., 2011;
Liu et al., 2014). Therefore, targeting BACE1ASmay be a promis-
ing therapeutic avenue for AD.
A less prevalent neurodegenerative disease, spinocerebellar
ataxia type 8 (SCA8), is characterized by a mutation within
a DNA region yielding a ncRNA. Here, a lncRNA referred
to as ATXN8OS has a CTG trinucleotide repeat expansion
(Koob et al., 1999; Mutsuddi and Rebay, 2005). This RNA is
opposite to the coding strand for a protein referred to as KLHL1
(Nemes et al., 2000). Co-expression analysis of ATXN8OS and
KLHL1 RNA in several regions within the human brain sug-
gests that ATXN8OS represses the sense transcription of KLHL1
(Chen et al., 2008b). Intriguingly, siRNA-mediated knockdown
of KLHL1 in murine pheochromocytoma PC12 cells markedly
decreases neurite outgrowth (Seng et al., 2006). Thus, the CTG
repeat expansion in ATXN8OSmay lower KLHL1 expression and
this may in turn limit neurite outgrowth and contribute to brain
dysfunction.
The neural-speciﬁc protein ubiquitin-protein hydrolase
UCHL1 is also regulated by its antisense transcript (Carrieri et al.,
2012). Individuals carrying UCHL1 mutations, which reduce
the hydrolase activity of the enzyme, develop early progressive
neurodegeneration (Bilguvar et al., 2013). Interestingly, UCHL1
has also been demonstrated to be oxidatively inactivated in
the brains of individuals with PD or AD (Choi et al., 2004;
Barrachina et al., 2006). Future work should clarify whether
perturbations to the UCHL1 antisense transcript alter UCHL1
expression or function in ways that promote neurodegeneration.
lncRNAs form Nuclear Bodies that may
Protect Against Neurodegeneration
The formation of disease-linked nuclear bodies can be promoted
by some lncRNAs, including NEAT1 (Ip and Nakagawa, 2012).
These include the lncRNA NEAT1, whose expression is greatly
increased in young proliferating cells, HD neurons, and early
stage ALS motor neurons (Johnson, 2012; Abdelmohsen et al.,
2013; Nishimoto et al., 2013). NEAT1 is a required component
of paraspeckles, which are nuclear ribonucleoprotein-containing
bodies (Nakagawa and Hirose, 2012). Interestingly, the forma-
tion of paraspeckles has been proposed to represent an important
neuronal stress response based on several observations includ-
ing the fact that NEAT1 is upregulated in early stage ALS
and in the brains of heroin users (Michelhaugh et al., 2011;
Nakagawa and Hirose, 2012; Nishimoto et al., 2013). Consistent
with a putative role in stress responses, paraspeckles store
highly edited RNAs that are rapidly released under vari-
ous stress conditions (Prasanth et al., 2005). Aberrant stress
responses are linked to several neurodegenerative diseases
and NEAT1/paraspeckle-related defects may thus promote
neurodegeneration. Consistent with this notion, FUS local-
izes to nuclear paraspeckles and is a direct binding part-
ner of NEAT1 (Nishimoto et al., 2013; Shelkovnikova et al.,
2014). In many ALS/FTLD cases, FUS is mutated and
mislocalized to the cytoplasm and this may compromise
nuclear paraspeckles and their role in responding to stress
(Shelkovnikova et al., 2014). Indeed, siRNA-mediated knock-
down of FUS eliminates paraspeckle formation in a number
of human cell lines (Shelkovnikova et al., 2014). Furthermore,
both a transgenic mouse model of ALS-FUS and motor neu-
rons from ALS-FUS patients demonstrated that FUS sequestered
vital nuclear paraspeckle proteins into cytoplasmic inclusions
(Shelkovnikova et al., 2014). Importantly, cytoplasmic aggrega-
tions of FUS have also been reported in a number of trinucleotide
repeat disorders including HD (Doi et al., 2008, 2010). Thus,
failed nuclear paraspeckle formation may contribute to several
neurodegenerative diseases.
Taken together, these studies indicate that functional lncR-
NAs may naturally counteract neurodegeneration through basic
roles in the regulation of gene expression and the modulation
of cellular stress responses. In contrast, some lncRNAs as well
as other RNAs with either unclear or no natural function may
contribute to neurodegeneration as we will discuss in the next
section.
Deleterious Processes Triggered by
Non-Coding RNA in
Neurodegenerative Disease
Toxic RNA Sequesters RNA-Binding Proteins
Non-functional RNA can interact with RNA-binding proteins
whose functions depend on their speciﬁc subcellular distri-
bution. Toxic RNA in patients with neurodegenerative disor-
ders may abnormally sequester these important RNA-binding
proteins away from their site of action. For example, the
most common genetic cause of both sporadic and familial
forms of ALS is a hexanucleotide repeat expansion in an
intron of the C9ORF72 gene (DeJesus-Hernandez et al., 2011;
Majounie et al., 2012). This mutation confers a toxic gain-of-
function onto the C9ORF72 transcript: the repeat expansion
itself when transplanted to another portion of the genome
is suﬃcient to cause neurodegeneration in D. melanogaster
(Xu et al., 2013). C9ORF72 hexanucleotide repeat expansion
causes abortive transcripts rich in G-quadruplexes, which are
higher order structures built around hydrogen bonded guanine
tetrads. Interestingly, FUS associates with G-quadruplexes
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pointing to a potential connection between FUS and C9ORF72
(Takahama et al., 2013). These G-quadruplexes bind to and
sequester the RNA-binding protein nucleolin (Haeusler et al.,
2014). With nucleolin distribution altered, cells show dis-
tinct signs of nucleolar stress (Haeusler et al., 2014). While it
remains unclear if this nucleolar stress directly causes neu-
rodegeneration, these studies demonstrate a novel mechanism
through which toxic RNA may lead to neurodegenerative dis-
ease via the aberrant sequestration of various RNA-binding
proteins.
Many neurodegenerative diseases are characterized by the
presence of a trinucleotide repeat expansion. These include
HD (which has a CAG expansion in the HTT protein), sev-
eral types of SCA, and ATXN2-associated ALS (Elden et al.,
2010; Nalavade et al., 2013). Trinucleotide repeats can also trig-
ger neurodegeneration via toxic RNA-mediated sequestration
of RNA binding proteins. For example, CAG repeat RNA has
been shown to bind to and sequester nucleolin (Tsoi et al., 2012;
Tsoi and Chan, 2013). While many diseases with CAG repeats
have the repeat within coding regions, studies done in the nema-
tode C. elegans demonstrated that CAG repeats within a 3′ UTR
are suﬃcient to shorten lifespan and inhibit motility in a repeat-
length associated manner (Wang et al., 2011a). Studies using
ﬂies also demonstrated that the introduction of an untranslated
CAG repeat is suﬃcient to cause neuronal degeneration (Li et al.,
2008). Therefore, toxic RNA is capable of being produced from
either coding or non-coding regions and it can act as a toxic agent
via sequestration of key RNA binding proteins. This sequestration
could lead to nucleolar stress or other ribonucleoprotein-related
defects yet to be characterized.
Repeat-Associated Non-ATG Translation
Generates Toxic Dipeptides
In addition to sequestering RNA binding proteins, repeat-
containing transcripts can give rise to toxic proteins through
translation initiated from within the repeats (Figure 1). In D.
melanogaster, the hexanucleotide repeat present in C9ORF72
produces repeat rich RNA capable of undergoing RAN transla-
tion, in which translation occurs on repeats in all three reading
frames even in the absence of a start codon (Mizielinska et al.,
2014). This produces toxic dipeptide proteins that lead to cellu-
lar degeneration and shortened lifespan in ﬂies (Mizielinska et al.,
2014). Several other disease-linked mutations including SCA8-
associated ATXN8 and ATXN8OS CAG repeat expansions also
generate toxic dipeptides through RAN translation even when
full length ATXN8 is not expressed at all (Koob et al., 1999;
Zu et al., 2011). Therefore, portions of both the coding sense
and non-coding antisense transcript ATXN8OS are likely capa-
ble of producing toxic dipeptides through RAN translation
(Pearson, 2011). Additionally, a CGG repeat in the 5′ UTR of
the neurodegenerative disease fragile X-associated tremor/ataxia
syndrome (FXTAS)-linked FMR1 also gives rise to RAN trans-
lation products (Todd et al., 2013). Therefore, these observa-
tions raise the possibility that a number of diseases associated
with GC-rich repeats may be driven by pathogenic processes
arising from the accumulation of toxic RAN translation prod-
ucts.
R-Loops Repress the Expression of
Neuroprotective Genes and Threaten
Genome Integrity
Nascent ncRNAs transcripts are capable of hybridizing with their
parental DNA strands forming RNA–DNA hybrids (Figure 3;
Wahba et al., 2011; Aguilera and Garcia-Muse, 2012; Salvi et al.,
2014). These RNA–DNA hybrids form structures known as R-
loops, which can threaten genome integrity by inducing double
stranded breaks and aberrant recombination when collisions
occur between R-loops and advancing transcription/replication
machineries (Aguilera and Garcia-Muse, 2012). However, R-
loops can also regulate the expression of a diverse set of RNAs and
are suspected to play a broader role across the genome than it is
currently appreciated (Skourti-Stathaki and Proudfoot, 2014).
In several neurodegenerative disorders, R-loops can control
the fate of neuroprotective genes (Salvi and Mekhail, 2015). In
individuals with fragile X syndrome, a trinucleotide repeat expan-
sion within the promoter of the FXTAS-linked FMR1 triggers the
formation of R-loops, which cause the epigenetic silencing of this
gene (Colak et al., 2014). Similarly, R-loops formed upon intronic
trinucleotide repeat expansion within the Friedrich’s Ataxia gene
FXN promote its silencing and are thought to contribute to the
disease (Groh et al., 2014). R-loops are also responsible for the
abortive transcription observed at the hexanucleotide repeat-
expanded C9ORF72 locus (Haeusler et al., 2014). In addition,
data from yeast and Arabidopsis point to R-loops as regulators of
lncRNA expression but it remains unclear if R-loops regulate neu-
rodegenerative disease-linked lncRNAs such as the AD-linked
BACE1AS (Nakama et al., 2012; Sun et al., 2013).
Beyond individual genes, some neurodegenerative disorders
may encompass broad defects in R-loop or RNA–DNA hybrid
regulation. Early onset or juvenile ALS as well as the neurode-
generative disease AOA2 are linked to mutations within SETX,
which has emerged as a conserved RNA–DNA helicase from
yeast to human (Skourti-Stathaki et al., 2011; Yuce and West,
2013). Loss of SETX function leads to a drastic increase in the
number of R-loops formed within cells (Skourti-Stathaki et al.,
2011; Yuce and West, 2013). Interestingly, R-loops were easily
detected in dividing germ cells but not in post-mitotic brain cells
(Yeo et al., 2014). One possibility may be that the level of R-
loops driving neural degeneration is too small for detection using
present methods. It is also possible that R-loop formation drives
disease by disrupting support cells within the nervous system or
certain cell types along the neural lineage including neural stem
cells. Future work should clarify the intersection between SETX,
R-loops and neurodegeneration.
Similar to SETX-ALS/AOA2 links, another possibly early
link between R-loops and ATXN2-associated neurodegenera-
tion has recently emerged from a study conducted in the
budding yeast Saccharomyces cerevisiae. It was demonstrated
that Pbp1, the yeast ortholog of ATXN2, represses aber-
rant accumulation of hybrids harboring lncRNA and inter-
genic DNA within repetitive DNA loci including ribosomal
DNA (rDNA) repeats and subtelomeric regions (Salvi et al.,
2014). R-loop accumulation in Pbp1-deﬁcient cells triggered
aberrant DNA recombination events and shortened replica-
tive lifespan. Whether human ATXN2 functions similarly
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FIGURE 3 | Work done in yeast and humans has determined that
neurodegeneration-linked proteins and their orthologs are responsible
for RNA–DNA hybrid suppression. R-loop structures form when RNAPII is
transcribing DNA and the lagging RNA strand (in red) hybridizes with the DNA
strand (in black). SETX (implicated in AOA2 and ALS) has helicase activity and
can unwind RNA–DNA hybrid structures. Pbp1 (yeast ortholog of human ATXN2
implicated in SCA2 and ALS) has an RNA-binding domain that inhibits hybrids in
some other way, possibly by binding to unwound RNA to prevent it from
rehybridizing with its DNA strand. R-loops can lead to double stranded breaks
and genomic instability when they collide with advancing replication forks.
to suppress deleterious R-loops and if these structures con-
tribute to neuropathology remains to be determined. It is
also unclear if the R-loop suppressing functions of ATXN2
and SETX may intersect in ALS and other neurodegenerative
diseases.
Therefore, although R-loops can play positive/regulatory roles
in the cell, their aberrant regulation may trigger pathological
processes leading to neurodegeneration (Figure 3). Aberrant R-
loop accumulation can lead to the accumulation of toxic abortive
transcripts, suppress the expression of neuroprotective factors,
or compromise overall genome integrity. The emerging role of
R-loops in various diseases may also point to novel avenues for
therapeutic intervention.
Future Questions and Concluding
Remarks
While much progress has been made in our understanding of
the roles of ncRNAs in neural function, many questions still
remain. For example, we know that miRNAs play an impor-
tant role in neurogenesis, but the role that adult neurogenesis
and diﬀerentiation plays in many neurodegenerative diseases is
unknown. In fact, adult neurogenesis has yet to be detected
in most areas of the brain (outside the case of brain damage)
including many areas aﬀected in neurodegenerative diseases such
as the cerebellum (Ming and Song, 2011) This may be due to
detection problems, as the long-lived nature of neurons means
that rates of turnover are likely drastically lower when compared
to other tissue types. Adult neurogenesis would be an exciting
avenue to explore, as it may explain the neural cell-type speci-
ﬁcity commonly observed in neurodegenerative diseases. Thus
far, it has been demonstrated that premature aging in adult neu-
ral stem cells that harbor a LRRK2 mutation characteristic of
PD results in a decrease in neurogenesis and improper diﬀeren-
tiation (Liu et al., 2012). This hints that Parkinson’s might have
defects in adult neurogenesis, although it is also possible that
defects in diﬀerentiation that occur early in life due to this muta-
tion might predispose neurons to premature death much later in
life. Future work examining if neural stem cells are prematurely
dying or improperly diﬀerentiating in neurodegenerative settings
are needed.
More broadly, the reason that neurodegenerative diseases
do not manifest until late in life is poorly understood. Why
is HD onset typically in the fourth decade when the related
HTT mutation is present from birth? One model is that most
heritable polymorphisms in neurodegenerative disease-linked
factors cause minor molecular defects, as gross genetic failures
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would exit the gene pool by natural selection. Quality control
of protein synthesis decreases with time and there is therefore
an increased occurrence/accumulation of misfolded proteins
with age (Gaczynska et al., 2001). Such misfolding can con-
tribute to neurodegeneration. Consistently, the unfolded protein
response (UPR), an apoptotic defense mechanism against the
accumulation of misfolded proteins within the cell, is hyper-
activated, perhaps aberrantly, in a number of neurodegenera-
tive diseases including HD, AD, and PD (Halliday and Mallucci,
2014). Another non-exclusive possibility is that several nuclear
RNA binding proteins associated with neurodegeneration such
as TDP-43 and ATXN2 are recruited to cytoplasmic stress gran-
ules and this may prevent their proper RNA regulatory function
(Colombrita et al., 2009; Damrath et al., 2012). Stress granule for-
mation under oxidative stress and clearance by autophagy is
respectively increased and decreased with age (Colombrita et al.,
2009; Buchan et al., 2013; Szafranski and Mekhail, 2014). Thus,
the aberrant sequestration of proteins such as TDP-43 and
ATXN2 may increase with age and small defects may become
ampliﬁed over time leading to neurodegeneration. Oxidative
stress is also known to cause senescence within astroctyes
(Bitto et al., 2011). Senescent astrocytes are enriched in patients
with AD relative to age-matched controls (Bhat et al., 2012). This
may contribute to disease as these astrocytes have a senescence-
associated secretory phenotype wherein they release inﬂamma-
tory cytokines such as IL-6 (Bhat et al., 2012). Given that astro-
cytes are the most abundant cell-type in the brain and are more
susceptible to oxidative stress than other cell types such as ﬁbrob-
lasts, it is likely that astrocyte senescence is another age-related
risk factor for neurodegenerative diseases (Bitto et al., 2011).
Future work will undoubtedly clarify the link between aging and
neurodegeneration.
Many studies also hinted at links that need further clari-
ﬁcation. For example, is miR-34a repressing Bcl2 and SIRT1
in vivo and is this repression leading to neurodegeneration? Is
ATXN8OS regulating the transcription of KLHL1? Studies exam-
ining orthologs of human transcripts or proteins should also
be repeated in human models. For example, miR-8 was found
to regulate atrophin levels to prevent neurodegeneration in ﬂies
(Karres et al., 2007). Both miR-8 and atrophin are conserved; so
is the link to neurodegeneration also conserved? Studies report-
ing that ATXN2 orthologs impact D. melanogaster RISC and
S. cerevisiae R-loop accumulation should serve as foundation
for similar studies conducted in mammalian/human model sys-
tems. The link between paraspeckles and neuronal stress response
also needs to be clariﬁed, as the current literature is mostly
correlative.
Overall, commendable gains have been made in understand-
ing the pathobiological processes underlying various neurode-
generative diseases. However, signiﬁcant research remains to be
done in various organisms in order to fully decipher human dis-
ease mechanisms. Such mechanistic studies promise to uncover
new avenues for targeted therapeutics. For example, understand-
ing the role of neural stem cells in neurodegenerative disease
could allow for the development and perfection of stem cell
based therapies. Currently, neural stem cell injection therapy
for ALS has successfully demonstrated safety and is moving
to Phase II trials (Feldman et al., 2014). However, we do not
yet know if these stem cells would be resistant to the fac-
tors that induce cell death in motor neurons or whether stem
cell defects are present in ALS neurons. Other possible ther-
apeutic avenues include ASOs against proteins that are mis-
folded in neurodegenerative disease. Indeed, studies targeting
HTT with ASOs have demonstrated eﬃcacy in primate models
(Kordasiewicz et al., 2012). ASO-mediated targeting of C9ORF72
suppressed ALS-linked defects typically observed in patient-
derived induced pluripotent stem cells (Donnelly et al., 2013).
On another front, it is also possible to target speciﬁc miR-
NAs. For example, repressing miR-34 may alleviate some of
the brain degeneration seen in AD (Table 1; Wang et al., 2009;
Li et al., 2011b). While no drugs targeting miRNAs in neurode-
generative disease have been developed yet, trials have demon-
strated the safety and eﬃcacy of targeted inhibition of a spe-
ciﬁc miRNA in the treatment of Hepatitis C (Janssen et al.,
2013).
As illustrated in this article, ncRNAs, neurodegenerative dis-
eases, and aging are interconnected. miRNAs, lncRNAs, and
related factors can impact the nervous system in various pos-
itive and negative manners depending on the precise underly-
ing molecular processes. Continued eﬀorts to understand the
molecular pathways underlying natural neural function, dev-
astating neurodegenerative diseases and their connection to
aging will undoubtedly lead to the development of smarter
therapeutics.
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